International urogynecology journal · 2026
Multicentric Preliminary Experience and Clinical Outcomes of Female Urethral Dilation Using a Paclitaxel-Coated Balloon.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carracedo David, Belkahia Ghali, Sánchez-Gallego María D, Otta Renán, García Rojo Esther, Jerez Tamara, Celada Guillermo, Sánchez-Guerrero Clara, Estebán Lucía, Minguez César, De la Morena José Manuel, Romero-Otero Javier
Аннотация
INTRODUCTION AND HYPOTHESIS: To evaluate the feasibility, safety, and preliminary clinical outcomes of paclitaxel-coated balloon (Optilume®) dilation in women with urethral stricture disease, a condition with limited minimally invasive treatment options.
METHODS: Multicenter, retrospective case series, including nine consecutive female patients treated with Optilume® between May 2023 and November 2025. Clinical characteristics, uroflowmetry, post-void residual (PVR), and patient-reported outcomes were collected. A uroflowmetric response was defined as a ≥ 50% increase in maximum flow rate (Qmax). Symptomatic improvement was assessed using the Patient Global Impression of Improvement (PGI-I) scale. Pre- and postoperative Qmax and PVR were compared using the Wilcoxon signed-rank test.
RESULTS: Nine women were included (mean age 63.2 years; SD 15.6). Median Qmax improved from 8.6 to 13.6 mL/s (p = 0.012). Median PVR decreased from 56 to 0 mL (p = 0.043). A uroflowmetric response was achieved in 66.7% (6/9). All procedures were outpatient, with no intra- or postoperative complications and no de novo stress urinary incontinence. One patient (11.1%) required reintervention for recurrence at 5 months, successfully managed with internal urethrotomy. All patients reported improvement on PGI-I: 66.7% (6/9) "very much better" and 33.3% (3/9) "better." At short-term follow-up (mean 11 months; variable), 88.9% (8/9) remained free of reintervention.
CONCLUSIONS: In this small, retrospective multicenter cohort, paclitaxel-coated balloon dilation appeared feasible and was not associated with major procedure-related complications in the short term, with encouraging functional and patient-reported improvements. These findings are preliminary and hypothesis-generating; prospective controlled studies with larger samples and longer, standardized follow-up are needed to better define effectiveness and durability.
METHODS: Multicenter, retrospective case series, including nine consecutive female patients treated with Optilume® between May 2023 and November 2025. Clinical characteristics, uroflowmetry, post-void residual (PVR), and patient-reported outcomes were collected. A uroflowmetric response was defined as a ≥ 50% increase in maximum flow rate (Qmax). Symptomatic improvement was assessed using the Patient Global Impression of Improvement (PGI-I) scale. Pre- and postoperative Qmax and PVR were compared using the Wilcoxon signed-rank test.
RESULTS: Nine women were included (mean age 63.2 years; SD 15.6). Median Qmax improved from 8.6 to 13.6 mL/s (p = 0.012). Median PVR decreased from 56 to 0 mL (p = 0.043). A uroflowmetric response was achieved in 66.7% (6/9). All procedures were outpatient, with no intra- or postoperative complications and no de novo stress urinary incontinence. One patient (11.1%) required reintervention for recurrence at 5 months, successfully managed with internal urethrotomy. All patients reported improvement on PGI-I: 66.7% (6/9) "very much better" and 33.3% (3/9) "better." At short-term follow-up (mean 11 months; variable), 88.9% (8/9) remained free of reintervention.
CONCLUSIONS: In this small, retrospective multicenter cohort, paclitaxel-coated balloon dilation appeared feasible and was not associated with major procedure-related complications in the short term, with encouraging functional and patient-reported improvements. These findings are preliminary and hypothesis-generating; prospective controlled studies with larger samples and longer, standardized follow-up are needed to better define effectiveness and durability.